NASDAQ:CCXI
Delisted
ChemoCentryx Stock News
$51.99
+0 (+0%)
At Close: Jan 27, 2023
Down 30% In A Month, Is There More Pain For ChemoCentryx Stock?
06:00am, Tuesday, 01'st Feb 2022
The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has seen a fall of 30% over the last
ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis
01:04pm, Thursday, 20'th Jan 2022
Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.
Why ChemoCentryx Shares Are Rising
04:29pm, Wednesday, 19'th Jan 2022 Benzinga
ChemoCentryx Inc (NASDAQ: CCXI ) shares are Full story available on Benzinga.com
ChemoCentryx''s Avacopan Scores European Approval For ANCA-Associated Vasculitis
03:47pm, Wednesday, 19'th Jan 2022 Benzinga
The European Union has approved ChemoCentryx Inc''s (NASDAQ: CCXI ) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021 . The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis Full story available on Benzinga.com
Why ChemoCentryx Shares Are Rising
11:29am, Wednesday, 19'th Jan 2022
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis. “European Union approval of TAVNEOS repre
ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis
10:47am, Wednesday, 19'th Jan 2022
The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021.
Wells Fargo Pounds the Table on ChemoCentryx Stock
01:22am, Wednesday, 19'th Jan 2022 TipRanksThe holy grail for a biopharma company is to get a drug approved and out to market, a feat achieved by few, considering the rigorous demands of regulators. However,
CERS, LTRPA and PECO among after hour movers
10:35pm, Tuesday, 18'th Jan 2022 Seeking Alpha
Gainers: Cerus Corporation (CERS) +7%. ChemoCentryx (CCXI) +3%
ChemoCentryx rebounds on bullish update for new ANCA vasculitis therapy
05:02pm, Thursday, 13'th Jan 2022 Seeking Alpha
After four consecutive sessions of losses, ChemoCentryx <> is on the rise after Raymond James noted the latest prescriber information on the companys ANCA vasculitis drug
G Medical, ChemoCentryx top healthcare gainers; Denali, Immix among losers
03:02pm, Thursday, 13'th Jan 2022 Seeking Alpha
G Medical Innovations (GMVD) +20%. ChemoCentryx (CCXI) +12%. Denali Therapeutics Inc. (DNLI) -13%. Immix Biopharma (IMMX) -11%.
ChemoCentryx (CCXI) Presents At J.P. Morgan 40th Annual Healthcare Conference - Slideshow
07:38pm, Wednesday, 12'th Jan 2022 Seeking AlphaWhy ChemoCentryx Stock Tanked in 2021
10:30am, Wednesday, 12'th Jan 2022
A long, drawn out regulatory review weighed on the drugmaker's shares last year.
3 Biotech Stocks That Could Double in 2022
06:04am, Monday, 03'rd Jan 2022
They're risky. But with the high risk comes the potential for high rewards.
ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod
08:25am, Monday, 27'th Dec 2021
ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.
ChemoCentryx Inc. (CCXI) Outlook: Revisiting The Past For Future Insights
12:00pm, Friday, 24'th Dec 2021 Stocks Register
ChemoCentryx Inc. (NASDAQ:CCXI) concluded the trading at $37.72 on Thursday, December 23 with a rise of 3.26% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $36.53 and 5Y monthly beta was reading 1.80 with its price kept floating in the range ChemoCentryx Inc. (CCXI) Outlook: Revisiting The Past For Future Insights Read More »
